A perspective on the impact of radiation therapy on the immune rheostat. by McBride, William H et al.
UCLA
UCLA Previously Published Works
Title
A perspective on the impact of radiation therapy on the immune rheostat.
Permalink
https://escholarship.org/uc/item/49z0j2dw
Journal
The British journal of radiology, 90(1078)
ISSN
0007-1285
Authors
McBride, William H
Ganapathy, Ekambaram
Lee, Mi-Heon
et al.
Publication Date
2017-10-01
DOI
10.1259/bjr.20170272
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BJR https://doi.org/10.1259/bjr.20170272
Received:
15 April 2017
Revised:
31 May 2017
Accepted:
6 June 2017
© 2017 The Authors. Published by the British Institute of Radiology under the terms
of the Creative Commons Attribution-NonCommercial 4.0 Unported License
http://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted
non-commercial reuse, provided the original author and source are credited.
Cite this article as:
McBride WH, Ganapathy E, Lee M-H, Nesseler JP, Nguyen C, Schaue D. A perspective on the impact of radiation therapy on the immune
rheostat. Br J Radiol 2017; 90: 20170272.
REVIEW ARTICLE
A perspective on the impact of radiation therapy on the
immune rheostat
WILLIAM H MCBRIDE, DSc, EKAMBARAM GANAPATHY, PhD, MI-HEON LEE, PhD, JEAN P NESSELER, MD,
CHRISTINE NGUYEN, BSc and DO¨RTHE SCHAUE, PhD, MRes
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Address correspondence to: Dr William H McBride
E-mail: wmcbride@mednet.ucla.edu
ABSTRACT
The advent and success of immune checkpoint inhibitors (ICIs) in cancer treatment has broadened the spectrum of
tumours that might be considered “immunogenic” and susceptible to immunotherapeutic (IT) intervention. Not all cancer
types are sensitive, and not all patients with any given type respond. Combination treatment of ICIs with an established
cytotoxic modality such as radiation therapy (RT) is a logical step towards improvement. For one, RT alone has been
shown to be genuinely immunomodulatory and secondly pre-clinical data generally support combined ICI-RT
approaches. This new integrated therapy for cancer treatment holds much promise, although there is still a lot to be
learned about how best to schedule the treatments, manage the toxicities and determine what biomarkers might predict
response, as well as many other issues. This review examines how RT alters the immune rheostat and how it might best be
positioned to fully exploit IT.
INTRODUCTION
In the past 2 years, .100 clinical trials have been registered
aiming to target negative regulators of T-cell immune acti-
vation, known as immune checkpoint inhibitors (ICIs) with
local radiation therapy (RT) for cancer treatment (https://
clinicaltrials.gov).1 This burst of enthusiasm for RT-ICI
combination therapy has been occasioned by the confluence
of several factors. Foremost was the success of the Food and
Drug Administration-approved ICIs, ipilimumab (anti-
CTLA-4, Yervoy), pembrolizumab (anti-PD-1, Keytruda),
nivolumab (anti-PD-1, Opdivo), atezolizumab (anti-PD-L1,
Tecentriq) and avelumab (anti-PD-L1, MSB0010718C) as
single anti-cancer agents; initial studies in melanoma and
renal cancer gave dramatic and durable responses with
tolerable toxicity in a significant number of patients.2 These
diseases were chosen because they were considered
“immunogenic”, largely because they respond to high-dose
IL-2. Clinicians were so encouraged that they treated many
other cancer types. Some patients with lung, oesophageal,
Merkel cell, cervical, gastric, bladder, triple negative
breast, colorectal and Hodgkin’s cancer responded, lead-
ing to the suggestion that these too might be “immuno-
genic”, although in reality only a minority of patients
respond to ICIs, while some cancer types seem totally
refractory. This was, however, sufficiently enticing to
make combinations with an established, locally delivered,
highly cytotoxic therapy such as RT, an obvious next step,
and encouraged in part by some initial largely anecdotal,
but dramatic, successes.3,4 Other factors driving these
trials included the highly competitive market for ICI de-
velopment, and the growing realization that RT per se,
even without ICIs, can shift the immune rheostat to in-
fluence the elimination of tumours.
Recently, it has become clear that the pathways by which
CTLA-4 and PD-1/PD-L1/2 inhibit immune responses are
largely distinct,5 and this might affect the way ICIs interact
with RT; something that may also vary with the clinical
setting. CTLA-4 is a CD28 homolog that acts early to in-
hibit immune responses, primarily by affecting the in-
teraction between T cells and antigen-presenting cells
(APC) in the lymph nodes, by competing in CD28-
mediated co-stimulation and is important for the action of
T-regulatory cells (Tregs). PD-1/PD-L1 or PD-1/PD-L2
interactions suppress T cells later on in the effector phase
of the response, especially in the periphery. And while anti-
CTLA-4 increases T-cell activation primarily by enhancing
proliferation and reducing Treg immunosuppression, anti-
PD-1/PD-L1 appear to restore activity to “exhausted” T
cells. How best to combine ICIs with RT and what to ex-
pect in terms of outcomes and toxicities have become the
subject of much discussion.6,7
INFLAMMATION LINKS RADIATION THERAPY
AND IMMUNITY
Radiation oncologists have spent the past century trying to opti-
mize the way to deliver high doses to tumours with acceptable
normal tissue toxicity. A seminal discovery in the 1930s that has
stood the test of time is that delivering dose in low fractions of
about 2Gy daily over 5–6 weeks spares normal tissues, in par-
ticular those that are proliferating more slowly, compared with the
tumour.8 In the early days of RT, the minimal skin erythema dose
was an accepted measure to ensure that normal tissue reactions
were not excessive. This inflammation, along with the overheating
of the low-power X-ray machines of the time, probably promoted
the use of dose fractionation, together with experimental evidence
that fractionation spared skin testicular reactions in rams being
sterilized by irradiation.9 It became accepted that higher doses of
RT are pro-inflammatory, whereas lower doses of ionizing radia-
tion could actually inhibit inflammation. Fraction sizes of around
2Gy became the convention in the field, with justification for
sparing of slowly proliferating normal tissues compared with
rapidly proliferating tumours provided by the four R’s of radio-
therapy—repair, repopulation, redistribution and reoxygenation.10
Nevertheless, the desire to shorten treatment times continued to
drive multiple efforts towards employing higher sized doses for
cancer RT. Most often, these resulted in poorer outcomes, al-
though radiobiological modelling was able to direct altered frac-
tionation schemes to moderate success in Phase III clinical trials,
validating their use for fraction sizes around 1–3Gy.11
The clinical landscape changed, however, with the introduction of
intensity-modulated RT (IMRT) that uses computer-controlled
linear accelerators to deliver radiation doses that conform more
precisely to the three-dimensional shape of the tumour and to
minimize the volume of normal tissues receiving high radiation
doses. IMRT has been used to advantage, most notably to give
large ablative RT doses to small volumes, or in the treatment of
individual or oligometastatic disease sites. Hypofractionation
giving doses of 5–10Gy in 10–5 fractions also draws from this
technique and is especially useful to shorten treatment times in
situations where conventional (2-Gy) fractionated RT confers
little biological advantage because tumour and normal tissue re-
spond to fractionation similarly, or when critical structures can be
avoided, or the target volume can be restricted. Although estab-
lished safety criteria for RT should not be violated when ICIs are
added, the evidence suggests that the pro-inflammatory effects of
RT kick in only above a certain dose threshold and that hypo-
fractionation with IMRT may be better at generating a state of
radiation-induced inflammation that can be exploited immuno-
logically.12 In other words, isoeffective doses of cytotoxic therapy
can be given with a size of dose per fraction chosen to encourage
the creation of a “dangerous” microenvironment optimal for
engaging the adaptive immune system,13 which may be of special
advantage in the context of concurrent ICI administration with
RT. About half the current clinical trials with ICIs plus RT use
hypofractionation, and it will be of interest to see if an effect of
size of dose per fraction can be discerned.
From a philosophical point of view, evolution did not create
processes to directly control tumours, as most arise after the
reproductive age, or to cope with high radiation doses. These
were unlikely to rank as high evolutionary priorities, unlike the
canonical inflammatory processes that combat pathogens, me-
diate wound healing and maintain immune homeostasis. The
normal roles of CTLA-4 and PD-1/PD-L1 are to prevent auto-
immunity and control chronic inflammation so as to minimize
immune-related normal tissue damage, not to frustrate anti-
tumour IT. The common ground for collaboration between RT
and immunotherapy (IT) comes indirectly through in-
flammation and the links between innate immune mechanisms
to adaptive immunity. Inflammation is a prerequisite for mat-
uration of dendritic cells for optimal antigen presentation, T-cell
stimulation and the generation of tumour-specific immunity,
and doses of radiation that create a “dangerous” inflammatory
microenvironment may better assist the development of anti-
tumour immunity.12 Hard data as to the optimum dose for this
are sparse, but production of radiation-induced inflammatory
cytokines in tissues peaks around doses of 6–8Gy, with frac-
tionation extending the response.14–16 Comparison of fraction-
ation schemes should really be performed at isoeffective levels of
cell killing in the presence and absence of an adaptive immune
system, something that is rarely carried out, but there is suffi-
cient evidence suggesting that there might be a sweet spot where
fractionation is most likely to assist immunity. Hypofractiona-
tion with 6–8Gy appears superior to conventional doses17 and
are more effective than lower or higher doses at generating
“abscopal” effects in pre-clinical tumour models, which is when
RT delivered to one tumour affects the growth of another at
a distant site.18,19 This suggests that single doses may be less
effective than hypofractionated doses at generating immunity,
but further confirmation of this in different models is needed.
The finding that radiation acts as an immunological adjuvant to
increase tumour-specific immune responses has been shown in
several tumour models20,21 but is far from being a universal
phenomenon.22,23 It is worth considering some of the rea-
sons why.
TUMOUR IMMUNOGENICITY, IMMUNOTHERAPY
AND RADIATION THERAPY
For the same level of intrinsic tumour radiation sensitivity,
tumours that generate effective anti-tumour immunity appear to
be more radiosensitive.17,24 Immunity is therefore a likely cause
of radiocurability.25–27 Indeed, if T-cell depletion increases the
dose required to cure tumours (TCD50), it is reasonable to
assume that an effective immune response is present. For tu-
mour regression, immunity along the CD81 T-cell-mediated
axis is generally required. From infectious disease studies, we
know that this form of immunity is primarily required for the
elimination of virus-infected cells. In this respect, it will be
fascinating to see the extent to which the known radiosensitivity
of HPV1 tumours compared with HPV– tumours has an im-
munological content. Indeed, there may be fundamental dif-
ferences in T-cell recognition depending on the nature of their
induction, e.g. virus-induced vs chemically induced tumours.
Differences in intratumoural immune cell infiltrates suggest
immune involvement,28 and there are clear genomic differences,
although other intrinsic mechanisms have been suggested in-
cluding differential DNA repair and differences in cell cycle
control and in repopulation. It is of course a vast over-
simplification to consider the CD81 T-cell subset as working in
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isolation. Anti-tumour responses are multifaceted involving,
additionally, CD41 T-cell helper and regulatory subsets and
myeloid cells, not to mention many other cell-associated and
soluble molecules, with the vasculature and stromal cells playing
major roles. The overall response is an integration of these di-
verse elements; however, the pre-clinical data clearly ascribes
tumour regression to the CD81 T-cell subset. This raises
questions as to the nature of the antigens being recognized, their
source and their dependency on the nature of cancer causation.
Tumour regression requires antigen expression and provision of
targets, and forced expression of a foreign model antigen, such
as ovalbumin, or immune cytokines, such as IL-2, IL-3, IL-4, IL-
7 etc.,14 generates more immunity and makes tumours more
radiosensitive. Similarly, the combination of ICIs and RT
improves outcomes in pre-clinical studies29–32 through non-
redundant mechanisms.33 The question as to whether ICI and/
or RT can generate immunity against non-immunogenic
tumours, however, remains largely unanswered. Although this
has been observed in one model after cytokine gene trans-
fection,34 the extent to which this is generally possible remains
uncertain. If anti-tumour immunity is present prior to treat-
ment, removal of immune checkpoints by ICIs or removal of the
tumour burden by any means may result in immune activation
and regression. On the other hand, there may be little advantage
to the use of ICIs if valid regression antigens are not present, but
if immunity is generated by RT, for which there is some tenuous
clinical evidence,35 the combination will be more broadly
valuable. This steers the discussion towards the nature of
tumour-rejection antigens.
Graft rejection and tumour immunology used to be one scien-
tific field before inbred mouse strains were shown to develop
tumours that could be successfully transplanted into mice of the
same strain but not into mice of a different strain where his-
tocompatibility differences lead to only sporadic tumour take.36
However, even before these fields diverged, chemically induced
tumours were known to be immunologically unique,37,38 and
tumour biopsies could be used as vaccines that would increase
the incidence of radiation-induced regression.39 When syngeneic
transplantable tumours became models of choice, it rapidly
became clear that chemically or virally induced tumours were
much more immunogenic than spontaneous ones. This also
raised doubts as to the relevance of chemical-/virus-induced
tumours to the human situation which was assumed to be non-
immunogenic for the most part.40 This perspective lasted for
decades and changed dramatically only recently with the finding
that human tumours vary hugely in the number of mutations
they carry and with the notion that higher mutational load goes
hand in hand with higher immunogenicity and responsiveness
to IT, although the correlation is far from being perfect41–43 and
may not even apply to virus-induced tumours.44 Tumours that
have mutational signatures associated with ultaviolet, chemical
carcinogens, age and DNA repair defects, however, can have
a high number of tumour mutations and appear able to generate
clonal unique antigens that can activate T cells.45 Because of
their immunological component, they can respond to ICI
treatment46 and may be generally more radiosensitive, although
many other features have to be taken into account. So,
remarkably, the older pre-clinical studies with chemically and
virally induced tumours have regained their relevance and can
no more be dismissed. An important point needs to be stressed
here, namely that the spectrum of mutations in every tumour
type is wide, i.e. not every melanoma will be highly immuno-
genic, possibly indicating differences in tumourigenesis, nor will
the response to therapy necessarily be predictable. A case in
point is that lung cancers from smokers are more immunogenic
and ironically respond to ICI therapy better than those from
non-smokers.43 However, in a RT setting without ICIs, any
benefit to patients from tumour immunity is likely offset by
smoking causing hypoxia, which increases radioresistancy,
let alone the increased risks of second cancers and cardiovascular
events.47
The exact nature of tumour-associated antigens that can actually
direct T-cell-mediated tumour regression is still elusive. Clearly,
they form a small minority of conformally altered molecules
expressed by tumours. Chemical- or ultraviolet-induced human
and animal tumours may have unique non-cross-reacting re-
gression antigens, but little is known about what the immune
system sees in virus-induced tumours. However, the findings
clearly indicate that some human tumours express molecules
that autologous CD81 T cells can recognize and by which they
can be activated.48,49 Currently, the expression of very restricted
T-cell repertoires in tumour-infiltrating T cells (TIL) is taken as
evidence of this and of an ongoing clonal selection process, as
was suggested by early studies comparing tumour infiltrating,
blood and lymph node lymphocytes.48 In general, the presence
of pre-existing tumour immunity in patients when they come in
for treatment with ICIs and/or RT is a good prognostic sign, but
the real test for broad therapeutic applicability is whether im-
munity can be generated de novo. RT may help this process as
occasional conversions to responsiveness have been detected
following RT,35 but further studies are needed. Obviously,
patients with advanced cancer are often immunologically inert
as a result of their chronic condition and it will be interesting to
see if they can be immunologically reactivated by ICIs and/or
RT. It should be noted that tumour-immune regression as an
end point is very different from that of regression during che-
motherapy or RT. The timing of response will be different, and it
may take a considerable amount of time, but it is generally
associated with durable complete tumour elimination with
limited or no normal tissue toxicity.
RADIATION-INDUCED DANGER, INFLAMMATION
AND IMMUNITY
To make a successful immune response, such as against a tu-
mour, a pro-inflammatory, oxidatively stressed “dangerous”
microenvironment is created through the release of damage-
associated molecular pattern molecules, such as the “danger”
signals ATP and HMGB1. This promotes an immunological
ballet between different immune cells. It is orchestrated by the
ascendency of a long list of pro-inflammatory cytokines and
chemokines including IFN-g, GM-CSF, TNF-a, IL-1, IL-2, IL-3
and IL-4 and involves local draining lymph nodes and even
distant sites where the orchestra may be playing different tunes.
T-helper cells play a major controlling role by directing the re-
sponse. In this way, the immune rheostat is set at a point that
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allows maturation of dendritic cells (DCs) for antigen pre-
sentation, up-regulation of major histocompatibility complex
(MHC) Class I and II to facilitate immune recognition while
other cell adhesion systems feed forward to promote vascular
activation and further immune cell infiltration. This disturbance
of the normal homeostatic equilibrium is required to generate
immunity but with restraint systems kicking in an attempt to re-
exert control. These include induction of pathways such as PD-
L1 and PD-1, T regulatory and myeloid suppressor cells and the
anti-inflammatory cytokines IL-10 and TGF-b that aim to
counterbalance the pro-inflammatory, pro-oxidant, immune-
activating processes. This yin–yang of dueling, mutually antag-
onistic forces is inherent in the immune system and has
implications for cancer IT and RT, not the least being that as the
rheostat moves towards restoring control and a general wound
healing setting in which tumour growth and metastasis can be
accelerated, e.g. by myeloid suppressor cell involvement.
Ionizing radiation is able to mimic most of the microenviron-
mental “danger” responses and can act as a bona fide “danger”
signal. Not only can it assist in the generation of an immune
state but also turn tumour cells into better targets by increasing
expression of MHC Class I and death family receptors. Addi-
tional reinforcing signals may come from calreticulin and
phosphatidyl serine expression on tumour cells during
radiation-induced “immunogenic” cell death,50 which may be
a direct result of the oxidative stress conditions. Cells dying by
radiation-induced apoptosis do not do so “silently”, which is
important for the generation of a permissive environment and
antigen recognition. However, it must be stressed that although
RT may appear to drive immunogenicity, evidence that re-
gression antigens are generated de novo by RT is lacking, unlike
the case with mutagenic chemicals.51 Therefore, it seems that
RT, similar to ICIs, is more likely to rely on pre-existing antigens
to direct immune activation. Another big plus of RT is that it
can significantly enhance the ingress of immune cells into the
tumour.20 This is likely due to radiation-induced inflammation
increasing the vascular flow and tumour cell death decreasing
the interstitial fluid pressure, as well as activating cascades of
chemokines, cytokines and vascular cell adhesion molecules that
promote infiltration. It should be noted that RT may also
damage the intratumoural vasculature, especially at higher
doses,52 potentially hindering immune infiltration, which sug-
gests that IT may be best given prior to RT for which there is
some evidence.22 ICI treatment, such as RT, increases the T-cell
infiltrate into tumours,53,54 and the combination therapy might
therefore generate a superior source of tumour-infiltrating T
cells for adoptive transfer, especially if ICI-RT treatment was to
be given prior to tumour resection.
As might be expected, RT can mature DCs and enhance their
ability to cross-present immunodominant MHC-Class I pep-
tides so as to generate superior immunity and tumour
rejection.55,56 Cross-priming and cross-presentation is how the
immune system detects and responds to viral or mutational
antigens that occur in tumours or normal cells and that have to
be processed and presented by professional APC. The APC ac-
quire proteins from other tissue cells through endocytic mech-
anisms and process them either by proteasomal degradation or
endosomal proteases. Either way, they get loaded onto the MHC
molecules. The dominance of the processing pathway that is
used probably depends on the nature of the antigen, the nature
of the microenvironment and the state of the APC, with both
tolerance and immunity as possible outcomes. Both radiation
and proteasome inhibition enhance DC cross-presentation of
loaded peptides and their ability to generate immunity.55 By
contrast, irradiation of DCs prior to delivery of whole antigen by
adenoviral vectors, blocks their ability to generate immunity.53
This suggests that RT can determine the choice of antigen-
processing pathways, which may be a natural rheostat by which
DCs control immunity/tolerance induction in response to the
changing microenvironment and “danger” signalling. A case in
point is the ability of chloroquine—an endocytic compartment
inhibitor—to modulate radiation-induced tumour immunity
presumably by altering antigen degradation.57 Clearly, the effects
of RT on the processing and presentation of antigens are very
complex, and it is therefore no surprise that RT can do both,
namely enhance immunity as well as drive control mechanisms,
including PD-L1/PD-1 and regulatory T cells.
IMMUNE SUPPRESSION, IMMUNOTHERAPY AND
RADIATION THERAPY
Immune responses occur in specialized lymphoid organs and at
localized sites to prevent severe morbidity or mortality that
would arise from systemic immune activation. Control mecha-
nisms, such as CTLA-4, PD-1, Tregs and myeloid suppressor
cells have evolved to restrain and localize normal tissue damage
following inflammation and immune recognition. One conse-
quence of this trade-off is that the suppressor mechanisms allow
even highly immunogenic tumours to grow, as has been evident
from experimental animal models for decades. Both ICIs and RT
shift this immune rheostat. The art will be to optimally combine
these so that they synergize and not negate one another, and to
do so without increasing systemic and local toxicity beyond
acceptable limits. Biomarkers are urgently needed to assess the
position of the immune rheostat in patients as they begin
therapy.
The effects of RT on the rheostat determining suppression vs
immunity are complex with many moving parts. At the simplest
level, and known for many decades, RT decreases the number of
peripheral lymphocytes, even when given locally.58–60 In
humans, but not mice, this decrease can last for many years,
with most subsets affected, and with a decreased T helper :
suppressor ratio. This is thought to be due to lymphocytes in the
blood being killed as they pass through the radiation field. Of
note, the radiosensitivity of lymphocytes is so high that con-
ventional, low dose per fractions are as potent as high dose per
fraction in this regard, i.e. making volume the main determining
factor while the issue of fraction size becomes trivial.61 The
effect of this on anti-tumour responsiveness is not clear but, if
depletion is extensive, increased morbidity and infection are
seen. Interestingly, ICIs may mitigate this effect, suggesting
a limiting step during lymphocyte recovery that is otherwise
in place.
In many cases, RT-like surgery can remove large immunosup-
pressive tumour burdens or at least cause growth arrest. Since
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tumour regression is likely to be at some stage a numerical game
between the immune and tumour forces, RTmay simply tip the
balance in favour of the host. Removal of tumour burden may
also allow a pre-existing state of anti-tumour immunity to
emerge or, alternatively, a state of tumour immunity to be
generated. It is hard to distinguish between these possibilities,
but they are obviously very different processes. The complexity
of the tumour–host relationship in these situations is often
overlooked. For instance, there is evidence that small numbers
of highly immunogenic tumour cells can “sneak through” the
host defenses,62,63 adjusting the rheostat early on to suppression
rather than immunity.64 Ironically, the size of tumour inocula
most often used in experimental studies tends to be also optimal
for the generation of immunity.64 As immunogenic tumours
grow, immunity is (and has to be) counteracted by the gener-
ation of T regulatory/suppressor cells followed by the de-
velopment of a non-specific state of immunological inertia
probably associated with activation of the myeloid system. It is
hard to predict the effect of tumour removal in a host where
immunity is suppressed.
Local or systemic RT can increase the numbers and activities of
T regulatory cells even in the absence of tumour.65 This is in part
due to their radioresistancy relative to most lymphocytes so that
even 2Gy can increase their representation, but they are also
generated just in response to radiation-induced tissue damage.
RT can also induce PD-L1 expression on tumour cells and
suppress anti-tumour immunity.66 Yet, even in the presence of
suppression, concomitant immunity can coexist and, even
though it may not be obvious, it may be effective, e.g. in con-
trolling possible metastatic spread by immunogenic tumours.24
Many other “immune escape” mechanisms have been postulated
to explain the growth of tumours in the face of immune ag-
gression that are the subject of excellent reviews and will not be
reiterated here.67,68
The concept that immunity capable of tumour regression can
exist in at least some cancer patients while being held in check
by suppressor mechanisms is critical for the consideration of
combined ICI1RT treatments, remembering that some
patients may display anti-cancer responses that are not CD8-
mediated and are therefore less able to mediate tumour cure,
even though they may impact tumour growth. Under any cir-
cumstances, decreasing the tumour burden should be a primary
therapeutic aim and RT should therefore not be compromised
for ICI treatment. In further support of this approach, many
publications suggest that non-curative RT and surgery tend to
promote metastasis development, which is not the case for cu-
rative treatments.69 By the same token, to rely on immune
“abscopal” action to eliminate established tumours, may be
overly optimistic given the rarity of such events with RT alone70
and the general presence of the suppressive state. It should also
be noted that tumour shrinkage at a site distant from that ir-
radiated is not necessarily an evidence of generalized immune
activation, and involvement as other mechanisms, such as in-
terference with angiogenesis, are conceivable.71 Until the
abscopal effect is shown to be a common effect of ICI plus RT, in
our opinion oligometastatic disease sites should not be left un-
treated, even in the context of ICI treatment. Perhaps a more
realistic aim is to engage the immune system to assist in the
permanent elimination of established and micrometastatic
tumours and to develop lasting immunological memory to
minimize recurrence.
A broad generalization is that at the other end of the immu-
nogenic spectrum, there will be many tumours that have a low
mutational load, no evidence of virus, ultraviolet, chemical in-
duction or DNA repair-deficiency and respond poorly to ICIs.
Animal studies suggest that the myeloid axis may be of more
relevance for such tumours, although this almost bound to be an
oversimplification given the complex interplay within the im-
mune system. The role of myeloid cells in tumourigenesis,
metastatic potential and T-cell control is not within the remit of
this review but some points have to be made. Tumours have
been referred to as “wounds that do not heal”,72 which implies
involvement of myeloid cells in attempted healing responses.
The known plasticity and diversity within and between subsets
of the myeloid system,73 the difficulty in eliminating them by
genetic manipulations or drug treatments, and in reliably iso-
lating them from tissue sites without altering their functional
expression makes it hard to evaluate the role of these cells in
cancer development and therapy. Myeloid cells, especially mac-
rophages, are major cellular components in tumours where they
express much heterogeneity.74,75 The relationship between
chronic inflammation and cancer development implicates my-
eloid cells in carcinogenesis, as well as on tumour growth pro-
motion. RT activates myelogenesis, whether bone marrow is in
the field or not,76 and can stimulate macrophages to further
promote tumour growth.77,78 On the other hand, RT also
functionally alters macrophages to prime them for production
of pro-inflammatory cytokines, displaying the yin–yang rela-
tionships within the myeloid system.14,15 There are several
therapeutic approaches that block radiation-induced myeloid
cell mobilization and augment the effects of RT.76,79 The extent
to which these approaches result in effective antitumour im-
munity leading to tumour regression is not clear; blocked an-
giogenesis and loss of growth stimulation may contribute more
than T-cell activation to the therapeutic outcome.
PD-L1 is expressed by many cells upon activation and in re-
sponse to many signals. The interferons are especially effective,
but RT also increases expression.80 This is a reflection of the role
of these molecules in feedback control of inflammation and
immunity, which takes the PD-1/PD-L1/2 axis far outside the
realm of controlling just T-cell-mediated responses. PD-L1
upregulation on myeloid cells, along with the sheer number and
exquisite mobility of macrophages, makes them possible im-
portant targets for ICI therapy. Certainly, the integration of
CSF1R inhibitors, or other inhibitors of myeloid cell activation,
into ICI/RT regimes is of huge interest. However, if tumours
with a strong myeloid component prove to be a separate cate-
gory from those that predominantly recruit lymphoid cells, such
combinations may not be very effective indeed.
TOXICITIES OF IMMUNE CHECKPOINT INHIBITOR/
RADIATION THERAPY
Ultimately, the art of combining ICIs with RT may be to select
patients in whom the immune rheostat is set to a position where
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tumour-specific immunity can be liberated without excessive
adverse side effects. ICIs with RT may not result in de novo
generation of tumour regression antigens but should reset the
immune rheostat towards increasing immunity to existing
antigens. Both, however, will have local and systemic con-
sequences that have their basis in autoimmunity and in-
flammation and will lead to tissue damage.
The toxicities associated with conventional RT are generally well
known, as are the limits of hypofractionated RT. The toxicities
associated with ICI have also been documented and are often
referred to as “immune-related adverse events” (irAEs) that are
overwhelmingly related to breaking tolerance and the manifes-
tation of autoimmune reactions,81 with slight variations
depending on the nature of the ICI. Low-grade irAE is seen in
over half the patients receiving ICIs, but serious adverse reac-
tions are relatively rare with ,1% mortality.81 Ipilimumab has
been reported to have about twice as many grade $3 irAEs than
pembrolizumab.82 Combination of different ICIs increase tox-
icity and the addition of RTmight be expected to drive it further,
if for no other reason than it is pro-inflammatory. Any organ
system may be affected, but lesions involving the gut, skin, liver,
thyroid and lung are most common. These are generally easy to
mitigate with steroids, although cardiovascular toxicity from
autoimmune myocarditis, cardiomyopathy, heart failure, cardiac
fibrosis and cardiac arrest, while rare, may lead to significant
morbidity and mortality83 in line with the finding that PD-1 in
animals confers protection against inflammation and heart
damage.84
CONCLUSION
The enthusiasm with which ICI therapies have been integrated
into RT schedules is remarkable and the results on the ongoing
.100 clinical trials are awaited with interest. While biologics
have been introduced into radiation oncology clinics before,
none have come close to penetrating a specialty where most of
the clinical trials have been driven largely by advances in physics.
Some clarity is emerging on how best to combine ICIs with RT.
One thing ICIs and RT have in common is that they can alter
immune rheostats so as to enhance inflammation and the level
of anti-tumour immunity, but by different pathways. Tumour
immunogenicity may be the major factor deciding if specific
antitumour immunity is engaged that can enhance radiation-
induced regression and long-term cure, and since ICIs do not
seem to increase tumour immunogenicity, the potential of RT to
do so is likely to be important in determining the utility of the
combinations. Inhibitors of myeloid suppressor cells would be
expected to be similarly limited to more immunogenic tumours.
Pre-clinical data suggest that hypofractionated RT may be su-
perior to conventional or single-dose RT in enhancing tumour
immunity, although this requires further clinical confirmation.
Because both ICIs and RT are generally pro-inflammatory, it
seems very possible that combinations will uncover some un-
expectedly increased late inflammatory or autoimmune tox-
icities. It is therefore important that the established principles of
radiobiology as they relate to therapy are not compromised and
that precision RT is used to minimize high doses to normal
tissues. However, with care, IT promises much in being able to
augment and extend the reach of RT to cancer situations that are
currently treated only with a low chance of success.
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